Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gastrointestinal Neoplasms 1

Interventions

Specimen Handling 4Gemcitabine 4Fluorouracil 4Bevacizumab 4fludarabine 3aldesleukin 3Radiosurgery 3Oxaliplatin 3Endoscopic Mucosal Resection 3Cyclophosphamide 3Cetuximab 3130-nm albumin-bound paclitaxel 3Tomography, X-Ray Computed 2Surveys and Questionnaires 2Sunitinib 2Pemetrexed 2Leucovorin 2IDRX-42 2Folfox protocol 2Endoscopy, Digestive System 2Biopsy 2trastuzumab deruxtecan 1tislelizumab 1sodium thiosulfate 1sodium propionate 1semaglutide 1s-formylglutathione hydrolase 1repotrectinib 1regorafenib 1plecanatide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Diltiazem × 90 days × Clear all
NCT07456852 2026-06-02

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Mayo Clinic

Phase 1/2 Recruiting
60 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡